Free Trial

Terumo (OTCMKTS:TRUMY) Sees Strong Trading Volume - Here's Why

Terumo logo with Medical background

Key Points

  • Terumo Corp. experienced a significant increase in trading volume, with 926,763 shares traded—a 485% rise from the previous day's volume of 158,367 shares.
  • The company reported a quarterly earnings per share of $0.20, exceeding the consensus estimate of $0.17, although revenue of $1.76 billion fell short of the $1.80 billion estimate.
  • Terumo has a market capitalization of $24.46 billion and maintains a low debt-to-equity ratio of 0.07, indicating strong financial stability.
  • MarketBeat previews the top five stocks to own by November 1st.

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) shares saw an uptick in trading volume on Friday . 926,763 shares were traded during trading, an increase of 485% from the previous session's volume of 158,367 shares.The stock last traded at $16.52 and had previously closed at $16.34.

Terumo Price Performance

The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.53 and a current ratio of 2.64. The stock has a market capitalization of $24.46 billion, a price-to-earnings ratio of 28.98 and a beta of 0.79. The company has a 50-day moving average of $17.54 and a 200-day moving average of $18.00.

Terumo (OTCMKTS:TRUMY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.03. The company had revenue of $1.76 billion during the quarter, compared to the consensus estimate of $1.80 billion. Terumo had a return on equity of 9.19% and a net margin of 12.09%.

About Terumo

(Get Free Report)

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Terumo Right Now?

Before you consider Terumo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terumo wasn't on the list.

While Terumo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.